Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.

Autor: Lindberg Å; Department of Infectious Diseases, Lund University, Lund, Sweden.; Division of Medicine, Halland Hospital, Halmstad, Sweden., Eskelund CW; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark., Albertsson-Lindblad A; Division of Oncology, Lund University, Lund, Sweden.; Skåne University Hospital, Lund, Sweden., Kolstad A; Department of Oncology, Oslo University Hospital, Oslo, Norway., Laurell A; Department of Oncology, Akademiska University Hospital, Uppsala, Sweden., Räty R; Department of Haematology, Helsinki University Hospital, Helsinki, Finland., Grønbaek K; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark., Geisler CH; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark., Jerkeman M; Division of Oncology, Lund University, Lund, Sweden.; Skåne University Hospital, Lund, Sweden.
Jazyk: angličtina
Zdroj: Hematological oncology [Hematol Oncol] 2022 Feb; Vol. 40 (1), pp. 22-30. Date of Electronic Publication: 2021 Nov 10.
DOI: 10.1002/hon.2940
Abstrakt: Mantle cell lymphoma (MCL) is a rare, often aggressive type of B-cell lymphoma with poor survival and no cure. Cancer and cancer treatment has a negative impact on health-related quality of life (HRQOL) both during active disease and in the long term, and improvement of HRQOL is a crucial objective of cancer therapy in older patients and no curative intent. Baseline HRQOL has in other lymphoma populations been shown to be predictive of outcome. Here, we explored HRQOL, and its association with survival, by the EORTC QLQ-C30 questionnaire, before, during and after chemotherapy in a patient cohort with MCL, treated within the NLG-MCL4 trial, designed to evaluate the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment. Fifty-one patients were enrolled, median age was 71 years (range 62-84), 37 were men (73%). Pre-treatment HRQOL was similar to scores from the reference population with healthy individuals. During treatment, HRQOL deteriorated, but reverted to the same level as the reference population after treatment. There was a correlation between physical function (p = 0.001) and role function (p = 0.006) at baseline and WHO performance status, but not with other clinical or genetic prognostic factors. None of the baseline factors were predictive for treatment related to HRQOL in this cohort. Pre-treatment physical (p = 0.011) and role function (p = 0.032) were independent factors associated with overall survival, and physical function (p = 0.002) was also associated with progression free survival. These findings may possibly be used to design support during treatment and improve rehabilitation. Further investigations are needed for assessment of long-term HRQOL.
(© 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: